oops, a little sloppy on my behalf. 30 would be well after a series of beautiful announcementsI'm talking about a short gain of 25%, even to offset some longer term holdings, just as insurance.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%